Form 4 for WGS GeneDx Holdings Corp.
Accepted 2025-05-16 00:00:00 ET · period of report 2025-05-14 · accession 0000950170-25-073497 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-05-16 | 2025-05-14 | WGS | Corvex Management LP | Dir, 10% | P - Purchase | $60.16 | +50.0K | 3.03M | +2% | +$3.01M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-05-14 | P | A | 24,644 | $60.52 | 3,058,629 | I See footnotes | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $60.17 to $61.00. (F2) Investment funds advised by Corvex Management LP are the direct holders of 3,058,629 shares of the Class A common stock, par value $0.0001 per share ("Class A Common Stock") of GeneDx Holdings Corp. (the "Issuer") reported herein. Mr. Meister may be deemed to indirectly beneficially own these shares by virtue of Mr. Meister's control of the general partner of Corvex Management LP. (F3) For the purposes of this filing, each of Corvex or Mr. Meister disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein. This filing shall not be deemed an admission that Corvex or Mr. Meister is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
| 2 | Common | Class A Common Stock | 2025-05-14 | P | A | 25,356 | $59.81 | 3,033,985 | I See footnotes | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $59.16 to $60.15. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4. (F2) Investment funds advised by Corvex Management LP are the direct holders of 3,058,629 shares of the Class A common stock, par value $0.0001 per share ("Class A Common Stock") of GeneDx Holdings Corp. (the "Issuer") reported herein. Mr. Meister may be deemed to indirectly beneficially own these shares by virtue of Mr. Meister's control of the general partner of Corvex Management LP. (F3) For the purposes of this filing, each of Corvex or Mr. Meister disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein. This filing shall not be deemed an admission that Corvex or Mr. Meister is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |